UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000008343
Receipt No. R000009817
Scientific Title FEbuxostat versus placebo rAndomized controlled Trial regarding reduced renal function in patients with Hyperuricemia complicated by chRonic kidney disease stage 3 (FEATHER study)
Date of disclosure of the study information 2012/07/04
Last modified on 2018/10/12 12:12:14

No. Disposal Last modified on Item of update
1 Insert 2012/07/04 16:19:14
2 Update 2013/02/04 12:04:06 Recruitment status
Anticipated trial start date
Last follow-up date
3 Update 2013/04/30 17:30:00 Organization
TEL
TEL
Institute
Organization1
Institutions
4 Update 2013/06/06 17:57:08 Homepage URL
5 Update 2013/07/05 11:05:19 Public title
Acronym
6 Update 2014/01/30 08:48:19 Public title
Acronym
7 Update 2014/01/30 08:49:58 Recruitment status
8 Update 2015/07/06 09:31:57 TEL
Email
Last name of contact person
Last name of contact person
Name of person sending information
Name of person sending information
Organization
9 Update 2015/07/06 09:32:55 UMIN ID1
10 Update 2015/07/06 09:38:40 Last follow-up date
11 Update 2015/07/06 09:45:28 Key inclusion criteria
Key exclusion criteria
12 Update 2015/12/17 11:54:23 Last name of contact person
Last name of contact person
Name of person sending information
Name of person sending information
13 Update 2017/12/15 13:29:47 UMIN ID2
14 Update 2017/12/18 13:49:50 Organization
Organization
Division name
Division name
Address
Address
Last name of contact person
Last name of contact person
Name of person sending information
Name of person sending information
Name of primary sponsor
Organization
15 Update 2017/12/18 13:53:52 Anticipated trial start date
Last follow-up date
Date of closure to data entry
Date trial data considered complete
16 Update 2018/09/10 11:30:20 Recruitment status
URL releasing protocol
Publication of results
URL related to results and publications
17 Update 2018/10/12 12:12:14 Date analysis concluded


Contact us.